Arcturus Therapeutics (ARCT) Tops Q3 EPS by 48c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($1.33), $0.48 better than the analyst estimate of ($1.81). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $3.42 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• BofA lists top 5 themes driving next $1tn in incremental semi sales